[A21-151] Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V

Last updated 20.05.2022

Project no.:
A21-151

Commission:
Commission awarded on 30.11.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Immune system and infections

Indication:

Add-on therapy for patients from 6 years and above with relapsing remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA)

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2022-05-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form